Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Pharmaceuticals, Inc. on April 4, 2014. The filing discloses the entry into a material definitive agreement with Patheon U.K. Limited to collaborate on the manufacture and packaging of EXPAREL, a liposome injection of bupivacaine utilizing Pacira's DepoFoam technology.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The primary financial disclosure relates to capital expenditure commitments:
- Estimated Capital Expenditures: Approximately $40 million to $50 million for two dedicated manufacturing suites at Patheon's Swindon, UK facility, including equipment, construction, and milestone payments.
- Termination Costs: Potential liability of up to $2,000,000 for make-good costs and termination fees if the agreements are terminated under specific conditions.
Material Changes and Agreement Details
The company entered into three agreements: a Strategic Co-Production Agreement, a Technical Transfer and Service Agreement, and a Manufacturing Supply Agreement.
- Technical Transfer: Patheon will prepare two manufacturing suites. Pacira will provide equipment and pay fees based on milestone achievement. The agreement expires upon FDA approval of the suites.
- Manufacturing Supply: The initial term is 10 years from the date of FDA approval of the initial suite. Fees are based on operations and production volume.
- Timeline: Subject to regulatory approvals, the first commercial suite is expected to commence production in two to three years.
- Termination Rights: Pacira may terminate the Technical Transfer agreement for convenience with 30 days' notice. The Manufacturing Supply Agreement may be terminated for convenience with 18 to 36 months' notice, depending on the time elapsed since FDA approval.
Outlook, Risks, and Contingencies
Management provided forward-looking statements regarding capital expenditures and production timelines, noting that actual results may differ due to several risks:
- Delays in obtaining required regulatory approvals.
- Construction delays and cost overruns.
- Inability to fund the expected capital expenditures.
- Success of the collaboration with Patheon.
The company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the total capital expenditure commitment of $40-$50 million against current cash reserves and financing capabilities.
- Monitor the timeline for FDA approval of the Patheon manufacturing suites, as this triggers the 10-year supply term.
- Review the specific construction and manufacturing milestones required to avoid termination penalties.
- Assess the risk of regulatory withdrawal of EXPAREL, which allows for immediate termination of the supply agreement.
- Confirm the filing of the full agreement texts as exhibits to the Form 10-Q for the quarter ending June 30, 2014.